Depomed has announced that it has paid $4 million for US and Canadian rights to Lazanda fentanyl nasal spray from Archimedes Pharma Limited. Lazanda was approved by the FDA for the treatment of breakthrough cancer pain in June 2011, and Archimedes launched the product in the US in October 2011. The product is known as PecFent in Europe, where it was approved in 2010.
Depomed President and CEO Jim Schoeneck said, “Depomed is pleased to expand our portfolio of pain products with the addition of Lazanda nasal spray. We believe that Lazanda is differentiated in the breakthrough cancer pain space, allowing rapid onset of effect and avoiding administration of drug across the oral mucosa, which can be a challenge in some cancer patients. After a short transition period, Depomed will assume full responsibility for Lazanda in the US. We intend to leverage our commercial infrastructure to support the marketing of this product to pain specialists and select oncologists. We believe we will achieve significant returns for our shareholders from this acquisition.”
Read the Depomed press release.
